78 related articles for article (PubMed ID: 22139530)
1. A huge intraventricular congenital anaplastic astrocytoma: case report with histopathological and genetic consideration.
Yamashita S; Ryu S; Miyata S; Uchinokura S; Yokogami K; Uehara H; Moriguchi S; Iwakiri T; Marutsuka K; Ikenoue M; Sawa D; Yamada N; Kodama Y; Takeshima H
Brain Tumor Pathol; 2012 Apr; 29(2):107-12. PubMed ID: 22139530
[TBL] [Abstract][Full Text] [Related]
2. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
Xiong J; Liu Y; Wang Y; Ke RH; Mao Y; Ye ZR
Chin Med J (Engl); 2010 Dec; 123(24):3566-73. PubMed ID: 22166632
[TBL] [Abstract][Full Text] [Related]
3. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW
Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448
[TBL] [Abstract][Full Text] [Related]
4. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
van den Bent MJ; Gravendeel LA; Gorlia T; Kros JM; Lapre L; Wesseling P; Teepen JL; Idbaih A; Sanson M; Smitt PA; French PJ
Clin Cancer Res; 2011 Nov; 17(22):7148-55. PubMed ID: 21914791
[TBL] [Abstract][Full Text] [Related]
5. Successful chemotherapy for congenital malignant gliomas: a report of two cases.
Tamiya T; Takao S; Ichikawa T; Chayama K; Date I
Pediatr Neurosurg; 2006; 42(4):240-4. PubMed ID: 16714866
[TBL] [Abstract][Full Text] [Related]
6. O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation is significantly less frequent in ependymal tumours as compared to malignant astrocytic gliomas.
Koos B; Peetz-Dienhart S; Riesmeier B; Frühwald MC; Hasselblatt M
Neuropathol Appl Neurobiol; 2010 Jun; 36(4):356-8. PubMed ID: 20202118
[No Abstract] [Full Text] [Related]
7. [Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts].
Wick W; Weller M
Nervenarzt; 2010 Aug; 81(8):928-30, 932-5. PubMed ID: 20635074
[TBL] [Abstract][Full Text] [Related]
8. Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts.
Jones DT; Mulholland SA; Pearson DM; Malley DS; Openshaw SW; Lambert SR; Liu L; Bäcklund LM; Ichimura K; Collins VP
Acta Neuropathol; 2011 Jun; 121(6):753-61. PubMed ID: 21327941
[TBL] [Abstract][Full Text] [Related]
9. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
Juratli TA; Lautenschläger T; Geiger KD; Pinzer T; Krause M; Schackert G; Krex D
J Neurooncol; 2015 Sep; 124(2):197-205. PubMed ID: 26033545
[TBL] [Abstract][Full Text] [Related]
10. Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis.
Sasai K; Nodagashira M; Nishihara H; Aoyanagi E; Wang L; Katoh M; Murata J; Ozaki Y; Ito T; Fujimoto S; Kaneko S; Nagashima K; Tanaka S
Am J Surg Pathol; 2008 Aug; 32(8):1220-7. PubMed ID: 18580490
[TBL] [Abstract][Full Text] [Related]
11. Skeletal spread of an anaplastic astrocytoma (WHO grade III) and preservation of histopathological properties within metastases.
Martens T; Matschke J; Müller C; Riethdorf S; Balabanov S; Westphal M; Heese O
Clin Neurol Neurosurg; 2013 Mar; 115(3):323-8. PubMed ID: 22704562
[TBL] [Abstract][Full Text] [Related]
12. Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma.
Shamsara J; Sharif S; Afsharnezhad S; Lotfi M; Raziee HR; Ghaffarzadegan K; Moradi A; Rahighi S; Behravan J
Cancer Invest; 2009 Oct; 27(8):825-9. PubMed ID: 19544111
[TBL] [Abstract][Full Text] [Related]
13. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.
Felsberg J; Rapp M; Loeser S; Fimmers R; Stummer W; Goeppert M; Steiger HJ; Friedensdorf B; Reifenberger G; Sabel MC
Clin Cancer Res; 2009 Nov; 15(21):6683-93. PubMed ID: 19861461
[TBL] [Abstract][Full Text] [Related]
15. Loss of heterozygosity analysis in malignant gliomas.
Mizoguchi M; Kuga D; Guan Y; Hata N; Nakamizo A; Yoshimoto K; Sasaki T
Brain Tumor Pathol; 2011 Jul; 28(3):191-6. PubMed ID: 21629980
[TBL] [Abstract][Full Text] [Related]
16. The hypermethylation of the O6-methylguanine-DNA methyltransferase gene promoter in gliomas--correlation with array comparative genome hybridization results and IDH1 mutation.
Tuononen K; Tynninen O; Sarhadi VK; Tyybäkinoja A; Lindlöf M; Antikainen M; Näpänkangas J; Hirvonen A; Mäenpää H; Paetau A; Knuutila S
Genes Chromosomes Cancer; 2012 Jan; 51(1):20-9. PubMed ID: 21922591
[TBL] [Abstract][Full Text] [Related]
17. Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.
Park CK; Park SH; Lee SH; Kim CY; Kim DW; Paek SH; Kim DG; Heo DS; Kim IH; Jung HW
Neuropathology; 2009 Aug; 29(4):443-9. PubMed ID: 19170894
[TBL] [Abstract][Full Text] [Related]
18. Promoter methylation of O(6)-methylguanine-DNA-methyltransferase in lung cancer is regulated by p53.
Lai JC; Cheng YW; Goan YG; Chang JT; Wu TC; Chen CY; Lee H
DNA Repair (Amst); 2008 Aug; 7(8):1352-63. PubMed ID: 18555750
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas.
Lavon I; Zrihan D; Zelikovitch B; Fellig Y; Fuchs D; Soffer D; Siegal T
Clin Cancer Res; 2007 Mar; 13(5):1429-37. PubMed ID: 17332285
[TBL] [Abstract][Full Text] [Related]
20. Polar spongioblastoma: A high-grade glioma that does not contain the IDH1 mutation or 1p/19q LOH.
Nagaishi M; Tanaka Y; Iwatate K; Yokoo H; Ueki K; Hyodo A; Nakazato Y
Neuropathology; 2010 Oct; 30(5):547-52. PubMed ID: 20102524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
